Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
7
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
7
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
merck
pfizer
gilead sciences
biogen
cancer
eli lilly
europe blog main
europe top stories
gene therapy
What
bio
roundup
drug
pfizer’s
acquisitions
amid
biggest
bombast
buy
cancer
caught
ceo
companies
coronavirus
crispr
debate
develop
discussion
efforts
meso’s
miss
pandemic
presidential
price
promise
response
tuesday’s
vaccine
viewers
albert
alliance
alzheimer’s
approval
biogen’s
biopharmaceutical
bourla
bristol
build
calls
changing
Language
unset
unknown
Current search:
deals
×
startups
×
" san diego top stories "
×
" alzheimer's disease "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More